VSV-EBOVAC Consortium reports that a dose-dependent plasma signature of innate immune responses to the rVSV-ZEBOV vaccine reflects its biological outcomes and safety in Europe and…
The ADITEC Project on Advanced Immunization Technologies: an European Success Story. 30 million Euros of funding, 42 public and private institutions have joined forces for next…
A special high level event will be organized at the Italian Embassy in Brussels on the 8th of November. The event, will be dedicated to the…
Professor Claire-Anne Siegrist from the University of Geneva in Switzerland, the principal investigator of the Geneva clinical trial, and Donata Medaglini the coordinator of the VSV-EBOVAC project,…
This three day event will be attended by over one hundred participants from the 42 ADITEC partner institutions which includes some of the most competitive…
La Toscana leader nella definizione delle future priorità della ricerca e sviluppo nel settore dei vaccini in Europa. Nei giorni scorsi il partenariato europeo IPROVE (Innovation Partnership…
FIRENZE – La Toscana leader nella definizione delle future priorit della ricerca e sviluppo nel settore dei vaccini in Europa. Nei giorni scorsi il partenariato…
Coordinated by the SVA, the VSV-EBOVAC project “Vaccine safety and immunogenicity signatures of human responses to rVSV-ZEBOV” brings together 12 leading international vaccine research institutes, both clinical and high tech, from 6…
The article focuses on the way that the EU shapes the course of research and ADITEC is highlighted on its success of comparing different companies’…
Vaccines have the potential to transformthe health of all individuals and to reduce the health inequality between rich and poor countries. However, to achieve these…